October 18, 2017 / 12:59 PM / a month ago

BRIEF-U.S. FDA accepts regulatory submission for lynparza

Oct 18 (Reuters) - Merck & Co Inc:

* U.S. FDA accepts regulatory submission for lynparza® (olaparib) in metastatic breast cancer and grants priority review

* Merck & Co Inc - ‍a prescription drug user fee act (PDUFA) date is set for Q1 of 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below